- You are here:
- Home »
- Blog »
- colon cancer »
- Colon Cancer Survival Statistics
Colon Cancer Survival Statistics
What are colon cancer survival statistics? My name is Bernie Davis. I was diagnosed with colon cancer in 2025. I had the tumor surgically removed. I am researching and writing about staging, adjuvant chemotherapy, side effects, etc. etc.
Basically, I’m researching anything and everything that will help me survive my colon cancer! For the record, my goal is to balance quantity of life with quality of life.
While I’m not crazy about the doctor’s voice, look, etc., below, I am posting this video because it explains colon cancer staging pretty well. My stage at diagnosis was Stage pT4a pN2b → Stage IIIc adenocarcinoma- and I found the narrator’s explanation and chart helpful in my full understanding of the colon cancer staging system.
Colon Cancer – Survival and Staging
According to research, about 28–40% of patients with Stage IIIc are alive 5 years after surgery + chemo. I am young and healthy. My diet are also pretty nutritious. Of course, I think I can improve these in an effort to reduce my risk of relapse.
Are you a colon cancer survivor? What have you found to be effective or ineffective in your mission to survive colon cancer? Scroll down the page, post a comment or question, and I will reply to you ASAP.
thanks,
- Bernie Davis
- Colon Cancer Survivor
The survival rate for colon cancer depends on several factors, including the stage at which the cancer is diagnosed, the patient’s age, and overall health.
Stage at Diagnosis:
- Stage 0: 99%
- Stage I: 91%
- Stage II: 88%
- Stage III: 73%
- Stage IV: 13%
Age:
- Younger patients generally have better survival rates.
- For example, the 5-year survival rate for stage II colon cancer is 95% for patients under 50 and 82% for patients over 70.
Other Factors:
-
- Overall health and presence of other medical conditions
- Access to treatment and follow-up care
- Patient’s lifestyle (smoking, diet, exercise)
Estimated 5-Year Survival Rates by Stage:
- Localized (Stage 0-II):91-99%
- Regional (Stage III):73%
- Distant (Stage IV):13%
Natural Alternatives in the Treatment of Colorectal Cancer: A Mechanisms Perspective
Abstract
Colorectal cancer (CRC) is one of the deadliest neoplasia. Intrinsic or acquired resistance is the main cause of failure of therapy regimens that leads to relapse and death in CRC patients. The widely used chemotherapeutic agent 5-fluorouracil (5-FU) remains the mainstay for therapeutic combinations.
Unfortunately, chemotherapeutic resistance and side effects are frequent events that compromise the success of these therapies; the dysregulation of enzymes that regulate 5-FU metabolism increases the expression and activity of efflux pumps.
Additional tumor cell adaptations such as epithelial–mesenchymal transition (EMT), autophagy shaping of the tumor microenvironment, and inflammation contribute to chemoresistance.
Finding new strategies and alternatives to enhance conventional chemotherapies has become necessary. Recently, the study of natural compounds has been gaining strength as an alternative to chemotherapeutics in different cancers.
Curcumin, trimethylglycine, resveratrol, artemisinin, and some helminth-derived molecules, among others, are some natural compounds studied in the context of CRC.
This review discusses the main benefits, mechanisms, advances, and dark side of conventional chemotherapeutics currently evaluated in CRC treatment. We also analyzed the landscape of alternative non-conventional compounds and their underlying mechanisms of action, which could, in the short term, provide fundamental knowledge to harness their anti-tumor effects and allow them to be used as alternative adjuvant therapies…
Conclusions
Colorectal cancer has become a concerning disease in recent years; the high mortality rates of nearly 50% of the diagnosticated patients reflect mainly two problems:
(1) a delayed time of diagnosis leading to advanced stages of CRC;
(2) the failure of conventional schemes of therapeutic regimens to overcome acquired or intrinsic resistance that contributes to relapses, metastasis, and, finally, mortality in the patients.
The current chemotherapeutics—5-FU, oxaliplatin, and folinic acid—are clinicians’ best weapons to fight advanced CRC. Improving these chemotherapeutic treatments and avoiding their most significant chemoresistance problems would benefit patients’ health [150].
Natural compounds have recently attracted attention, given their functions as cancer preventives and potential adjuvants in chemotherapy. NCs have displayed direct and indirect effects in regulating frequent events characteristic of intrinsic and acquired chemoresistance, such as increased drug metabolism, regulated efflux pumps, autophagy, and the acquisition of EMT markers induced by inflammation and the tumor microenvironment [74,75].
Curcumin, resveratrol, artemisinin, TMG, and some molecules derived from ancient parasites like helminths, are natural compounds that have demonstrated their safe use in combinatory therapy together with 5-FU, improving the anti-tumoral response or restoring sensitivity to the drug (Figure 5).
All these data support the idea that most NCs, where safe doses for use have been proven, could be postulated as potential compounds for drug repositioning.
Interestingly, many of these natural alternatives share similar mechanisms of action, such as STAT signaling modulation and NFκB inhibition, and may have less toxicity than synthetic drugs. These characteristics make NCs an attractive field of research to support their use as adjuvant therapies against colorectal cancer in more preclinical and clinical studies (Figure 6).
colon cancer survival statistics colon cancer survival statistics colon cancer survival statistics